PABLO DE LA
CUEVA DOBAO
Profesor asociado de Ciencias de la Salud
Enrique
Herrera Acosta
Enrique Herrera Acosta-rekin lankidetzan egindako argitalpenak (15)
2024
-
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511
-
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
2023
-
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
International Journal of Dermatology
2022
-
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting
Dermatologic Therapy, Vol. 35, Núm. 8
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406
-
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients
Dermatologic Therapy, Vol. 35, Núm. 12
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117
2021
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
-
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain
Dermatology and Therapy, Vol. 11, Núm. 6, pp. 2207-2215
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741
2019
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800